Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...

Please provide your email address to receive an email when new articles are posted on . This approval makes Cosentyx the first interleukin-17A inhibitor and second biologic approved for hidradenitis ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Oct 24 (Reuters) - Novartis AG: * NOVARTIS RECEIVES APPROVAL FOR COSENTYX LABEL UPDATE IN EUROPE TO INCLUDE DOSING FLEXIBILITY IN ANKYLOSING SPONDYLITIS Source text for Eikon: Further company coverage ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved an intravenous formulation of Cosentyx for use in patients with psoriatic arthritis, ...

Please note Chef Michelle Bernstein is a COSENTYX® (secukinumab) patient and has been compensated for her time. Continue reading for Important Safety Information and a link to the full Prescribing ...

Basel, September 10, 2022 — Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx® (secukinumab) demonstrated rapid and sustained relief from the ...

The approval was based on data from the phase 3 SUNSHINE and SUNRISE trials, which included 1084 adults with moderate to severe HS. Results showed a significantly greater proportion of patients ...

The FDA has approved Novartis’ (NYSE:NVS) Cosentyx for the treatment of severe hidradenitis suppurativa, a debilitating skin disease, in adults. Novartis said Cosentyx, also known as secukinumab, is ...